Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Home medication reviews too costly

The current drive to implement home-based medication reviews by pharmacists is not cost-effective, a new study concludes.

An economic analysis of the HOMER trial of reviews conducted by pharmacists found they cost £1,695 per patient, compared with £1,424 for standard care controls.

There was no effect on hospital admissions and little benefit for quality of life.

Reviews therefore cost £33,541 per incremental quality-adjusted life year (QALY) gained – with only a 25 per cent chance they would be cost-effective at the NICE outer threshold of £30,000 per QALY.

Study leader Dr Richard Holland, senior lecturer in public health medicine at the University of East Anglia, said: 'The current policy imperative for implementing medication review needs to be reconsidered in light of the findings of this study – a small, non-significant gain in quality of life, no reduction in hospital admissions and a low probability of cost-


The analysis, which looked at the effect of reviews over a six-month follow-up period, was published in the latest issue of the journal Pharmacoeconomics.

• Looking for the latest reviews?

Go to

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say